Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Last Updated: 2026

Albireo Pharma

Rank#4708

Market Cap915.89M

CountryUnited States

Summary

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

History

Founded in 2007, Albireo is a specialized biopharmaceutical company focused on the development of novel bile acid modulators to treat rare diseases. The company is dedicated to transforming the lives of patients with liver and gastrointestinal diseases through pioneering scientific innovation.

Mission

Albireo’s mission is to bring life-changing treatments to people living with rare diseases.

Vision

Albireo’s vision is to become the leader in the discovery and development of bile acid modulators for rare diseases through innovative science and customer-focused collaborations.

References

https://in.investing.com/equities/biodel-inc

https://www.comparably.com/companies/vision/mission

https://www.crunchbase.com/organization/albireo

https://finance.yahoo.com/q?s=albo

https://www.albireopharma.com

https://sec.report/CIK/0001322505

Leadership team

Mr. Ronald H. W. Cooper (CEO, Pres & Director)

Mr. Simon Nicolas Reade Harford (CFO & Treasurer)

Ms. Martha J. Carter (Chief Regulatory Officer)

Products / Services

Biotechnology, Health Care, Therapeutics

Number of Employees

100 - 500

Address

Gothenburg, Vastra Gotaland, Sweden

Established

2008-01-01

Company Registration

SEC CIK number: 0001322505

Revenue

20M - 100M

Traded as

ALBO

Website

https://www.albireopharma.com

Social Media

Last Updated: 2026

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More

Last Updated: 2026

Albireo Pharma

Rank#4708

Market Cap915.89M

CountryUnited States

Summary

History

Mission

Albireo’s mission is to bring life-changing treatments to people living with rare diseases.

Vision

Albireo’s vision is to become the leader in the discovery and development of bile acid modulators for rare diseases through innovative science and customer-focused collaborations.

References

https://in.investing.com/equities/biodel-inc

https://www.comparably.com/companies/vision/mission

https://www.crunchbase.com/organization/albireo

https://finance.yahoo.com/q?s=albo

https://www.albireopharma.com

https://sec.report/CIK/0001322505

Leadership team

Mr. Ronald H. W. Cooper (CEO, Pres & Director)

Mr. Simon Nicolas Reade Harford (CFO & Treasurer)

Ms. Martha J. Carter (Chief Regulatory Officer)

Products / Services